StocksFundsScreenerSectorsWatchlists
AMGN

AMGN - Amgen Inc Stock Price, Fair Value and News

268.92USD+6.17 (+2.35%)Delayed

Market Summary

AMGN
USD268.92+6.17
Delayed
2.35%

AMGN Stock Price

View Fullscreen

AMGN RSI Chart

AMGN Valuation

Market Cap

144.1B

Price/Earnings (Trailing)

21.46

Price/Sales (Trailing)

5.11

EV/EBITDA

13.27

Price/Free Cashflow

19.58

AMGN Price/Sales (Trailing)

AMGN Profitability

EBT Margin

27.86%

Return on Equity

107.78%

Return on Assets

6.91%

Free Cashflow Yield

5.11%

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

28.2B

Rev. Growth (Yr)

19.84%

Rev. Growth (Qtr)

18.73%

AMGN Earnings

Earnings (TTM)

6.7B

Earnings Growth (Yr)

-52.54%

Earnings Growth (Qtr)

-55.66%

Breaking Down AMGN Revenue

Last 7 days

0.6%

Last 30 days

-1.5%

Last 90 days

-12.6%

Trailing 12 Months

10.5%

How does AMGN drawdown profile look like?

AMGN Financial Health

Current Ratio

1.65

Debt/Equity

10.14

Debt/Cashflow

0.13

AMGN Investor Care

Dividend Yield

3.21%

Dividend/Share (TTM)

8.64

Shares Dilution (1Y)

0.36%

Diluted EPS (TTM)

12.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202326.2B26.6B26.8B28.2B
202226.3B26.4B26.3B26.3B
202125.2B25.5B25.8B26.0B
202024.0B24.3B25.0B25.4B
201923.8B23.6B23.4B23.4B
201822.9B23.2B23.3B23.7B
201722.9B23.1B23.0B22.8B
201622.2B22.5B22.6B23.0B
201520.6B20.8B21.5B21.7B
201419.0B19.5B19.7B20.1B
201317.5B17.7B18.1B18.7B
201215.9B16.4B16.8B17.3B
201115.2B15.3B15.4B15.6B
201014.9B15.0B15.0B15.1B
200914.7B14.6B14.6B14.6B
2008014.8B14.9B15.0B
200700014.8B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amgen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
grygiel nancy a.
sold (taxes)
-189,016
268
-703
svp & cco
Mar 18, 2024
miller derek
sold (taxes)
-127,713
268
-475
svp, human resources
Mar 18, 2024
graham jonathan p
sold (taxes)
-1,580,690
268
-5,879
evp & gen. counsel & secy.
Mar 18, 2024
bradway robert a
sold (taxes)
-5,527,970
268
-20,560
chairman, ceo and president
Mar 18, 2024
santos esteban
sold (taxes)
-1,650,060
268
-6,137
evp, operations
Mar 18, 2024
reese david m
sold (taxes)
-1,667,530
268
-6,202
evp & chief technology officer
Mar 18, 2024
busch matthew c.
sold (taxes)
-39,255
268
-146
vp, finance & cao
Mar 18, 2024
gordon murdo
sold (taxes)
-1,737,170
268
-6,461
evp, global commercial ops
Mar 18, 2024
griffith peter h.
sold (taxes)
-1,389,520
268
-5,168
evp & cfo
Mar 18, 2024
khosla rachna
sold (taxes)
-117,765
268
-438
svp, business development

1–10 of 50

Which funds bought or sold AMGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
Edmonds Duncan Registered Investment Advisors, LLC
unchanged
-
-10,175
781,880
0.20%
Apr 18, 2024
Requisite Capital Management, LLC
unchanged
-
-3,700
284,320
0.06%
Apr 18, 2024
Measured Wealth Private Client Group, LLC
added
2.89
5,311
344,387
0.12%
Apr 18, 2024
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.
sold off
-100
-1,000
-
-%
Apr 18, 2024
WOODMONT INVESTMENT COUNSEL LLC
unchanged
-
-8,558
657,632
0.06%
Apr 18, 2024
Aviance Capital Partners, LLC
added
33.54
2,161,640
8,954,840
1.33%
Apr 18, 2024
PLIMOTH TRUST CO LLC
added
23.21
246,642
1,386,910
0.37%
Apr 18, 2024
Pettinga Financial Advisors LLC
unchanged
-
-3,527
270,957
0.07%
Apr 18, 2024
LITTLE HOUSE CAPITAL LLC
reduced
-24.12
-519,613
1,551,170
0.51%
Apr 18, 2024
FOSTER & MOTLEY INC
reduced
-0.77
-224,000
10,584,000
0.73%

1–10 of 49

Are Funds Buying or Selling AMGN?

Are funds buying AMGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMGN
No. of Funds

Unveiling Amgen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.16%
49,036,311
SC 13G/A
Jan 30, 2024
state street corp
5.52%
29,543,705
SC 13G/A
Jan 25, 2024
blackrock inc.
8.9%
47,811,356
SC 13G/A
Feb 09, 2023
vanguard group inc
9.01%
48,065,139
SC 13G/A
Feb 07, 2023
blackrock inc.
9.1%
48,513,079
SC 13G/A
Feb 06, 2023
state street corp
5.58%
29,760,088
SC 13G/A
Feb 11, 2022
capital research global investors
3.9%
22,157,906
SC 13G/A
Feb 10, 2022
state street corp
5.37%
30,221,708
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
46,661,009
SC 13G/A
Feb 01, 2022
blackrock inc.
8.9%
50,046,345
SC 13G/A

Recent SEC filings of Amgen Inc

View All Filings
Date Filed Form Type Document
Apr 17, 2024
DEF 14A
DEF 14A
Apr 17, 2024
DEFA14A
DEFA14A
Apr 10, 2024
ARS
ARS
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading

Peers (Alternatives to Amgen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
356.3B
85.2B
-5.03% -9.57%
10.14
4.18
6.46% 95.94%
318.7B
60.1B
1.61% 10.23%
873.24
5.3
1.40% -97.49%
146.8B
46.5B
-6.17% -34.78%
-105.7
3.15
42.59% -114.62%
144.1B
28.2B
-1.51% 10.46%
21.46
5.11
7.09% 2.52%
83.2B
27.1B
-9.77% -21.18%
14.68
3.07
-0.60% 23.36%
14.4B
15.8B
-4.60% 54.01%
-25
0.91
6.17% 76.47%
MID-CAP
4.2B
4.7B
-1.63% -14.16%
-328.55
0.9
4.58% 90.97%
4.0B
1.7B
-13.93% -17.76%
11.2
2.4
49.61% 324.78%
3.2B
8.8B
-9.38% 13.00%
-5.36
0.36
7.79% -163.11%
1.9B
644.4M
-9.13% -7.04%
13.99
2.99
29.14% 50.51%
SMALL-CAP
1.3B
743.2M
-12.63% -26.38%
-3.8
1.8
24.65% 80.36%
21.6M
1.3M
-20.43% -49.32%
-2.1
16.56
-98.14% -109.18%
16.6M
-
-10.09% 36.11%
-0.9
0.22
2882.68% -138.52%
2.6M
19.6M
-34.48% -94.22%
-0.18
0.13
80.00% 43.08%
472.0K
117.6M
-96.45% -95.94%
0
0
-0.79% -283.60%

Amgen Inc News

Latest updates
MarketBeat19 hours ago

Amgen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue18.7%8,1966,9036,9866,1056,8396,6526,5946,2386,8466,7066,5265,9016,6346,4236,2066,1616,1975,7375,8715,5576,230
Costs and Expenses41.8%6,9254,8824,3024,1844,6093,9924,4183,7384,5424,3285,6983,7724,6263,9703,8833,8064,1493,2613,1933,0853,848
  S&GA Expenses68.1%2,2741,3531,2941,2581,5721,2871,3271,2281,4251,3051,3841,2541,7731,3461,2951,3161,5131,2231,2601,1541,559
EBITDA Margin-4.9%0.53*0.55*0.56*0.54*0.46*0.47*0.46*0.42*0.43*0.43*-----------
Interest Expenses8.2%821759752543415368328295335296281285318302296346301313332343352
Income Taxes-60.8%85.0021723560113224921419923227194.00211262185227195280309385322257
Earnings Before Taxes-56.2%8521,9471,6143,4421,7482,3921,5311,6752,1312,1555581,8571,8772,2062,0302,0201,9832,2772,5642,3142,185
EBT Margin-14.6%0.28*0.33*0.35*0.35*0.28*0.29*0.28*0.25*0.26*0.25*-----------
Net Income-55.7%7671,7301,3792,8411,6162,1431,3171,4761,8991,8844641,6461,6152,0211,8031,8251,7031,9682,1791,9921,928
Net Income Margin-15.5%0.24*0.28*0.30*0.30*0.25*0.26*0.25*0.22*0.23*0.22*-----------
Free Cashflow-88.5%2892,5123,8387202,3092,8181,6841,9742,5212,176-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets7.3%97,15490,53490,26988,72065,12163,70059,29459,19661,16564,99359,77362,53962,94864,63765,01161,66959,70759,53559,37363,99766,416
  Current Assets-37.4%30,33248,47747,38044,70322,18624,06219,32218,52019,38524,38019,09921,29921,14422,66122,89518,81318,44031,05130,74635,15137,618
    Cash Equivalents-68.5%10,94434,70034,20031,6007,6299,5025,2036,5287,98911,9696,6306,1126,2669,0879,1457,6876,03711,4155,5257,3586,945
  Inventory89.4%9,5185,0264,9785,0114,9304,7574,5544,4114,0864,1524,1154,0173,8933,9423,8403,6823,5843,2433,1763,0162,940
  Net PPE6.8%5,9415,5635,5325,4605,4275,1885,1585,1425,1844,9824,9064,8554,8894,8164,8434,8794,9284,9014,8824,8924,958
  Goodwill498.8%18,6293,11115,53115,53115,52914,84514,86514,89714,89014,66514,67614,67314,68914,67414,67814,68314,70314,70526.0014,69214,699
  Current Liabilities8.5%18,39216,95417,09714,21515,68714,33112,61812,88612,18414,84214,58512,86911,6539,95310,52311,82712,83510,73710,62212,70613,488
  Long Term Debt7.0%63,17059,04059,37760,76137,35437,16135,70536,01033,22233,29128,45831,12932,89534,19634,13330,00826,95027,74227,79829,31929,510
    LT Debt, Current1.1%1,4431,4282,1678341,5911,54381784487.004,2884,3241,55691.0091.0091.001,8402,9532,0492,8163,7054,419
    LT Debt, Non Current7.0%63,17059,04059,37760,76137,35437,16135,70536,01033,22233,29128,45831,12932,89534,19634,13330,00826,95027,74227,79829,31929,510
Shareholder's Equity-18.6%6,2327,6566,7815,3483,6613,6532,4199166,7008,2178,2479,3349,40910,95910,6599,4859,67310,92710,79410,83212,500
  Retained Earnings-6.3%-26,549-24,971-25,540-26,919-28,622-28,066-28,252-29,568-24,600-22,964-22,762-21,639-21,408-19,851-20,168-21,378-21,330-20,136-20,054-19,895-17,977
Shares Outstanding0.1%535535535534534539535548570567575577---------
Float---118,556---129,940---137,531---138,057---110,809--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-80.5%5382,7604,1091,0642,6492,9781,9302,1642,8082,4181,9312,1042,1533,3682,8422,1342,5143,3771,4141,8453,194
  Share Based Compensation---------------------87.00
Cashflow From Investing-10239.3%-27,089-262-2111,358-3,473-267-2,193-111-23073.001,209-319-1,384-1,628-2,159-230-5,9635,3722,7453,555-4,637
Cashflow From Financing237.4%2,754-2,005-1,21021,509-1,0491,588-1,062-3,514-6,5582,848-2,622-1,939-3,590-1,798775-254-1,929-2,859-5,992-4,987-3,568
  Dividend Payments0%1,1401,1401,1391,1371,0401,0381,0381,0809909991,0081,016932936942945860868880901840
  Buy Backs-----900-50.006,3101,4461,0691,5928651,2087525919331,1231,1702,3493,0312,114

AMGN Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenues$ 28,190$ 26,323$ 25,979
Operating expenses:   
Cost of sales8,4516,4066,454
Research and development4,7844,4344,819
Acquired in-process research and development001,505
Selling, general and administrative6,1795,4145,368
Other879503194
Total operating expenses20,29316,75718,340
Operating income7,8979,5667,639
Other income (expense):   
Interest expense, net(2,875)(1,406)(1,197)
Other income (expense), net2,833(814)259
Income before income taxes7,8557,3466,701
Provision for income taxes1,138794808
Net income$ 6,717$ 6,552$ 5,893
Earnings per share:   
Basic (in usd per share)$ 12.56$ 12.18$ 10.34
Diluted (in usd per share)$ 12.49$ 12.11$ 10.28
Shares used in the calculation of earnings per share:   
Basic (in shares)535538570
Diluted (in shares)538541573
Product sales   
Revenues:   
Total revenues$ 26,910$ 24,801$ 24,297
Other revenues   
Revenues:   
Total revenues$ 1,280$ 1,522$ 1,682

AMGN Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 10,944$ 7,629
Marketable securities01,676
Trade receivables, net7,2685,563
Inventories9,5184,930
Other current assets2,6022,388
Total current assets30,33222,186
Property, plant and equipment, net5,9415,427
Intangible assets, net32,64116,080
Goodwill18,62915,529
Other noncurrent assets9,6115,899
Total assets97,15465,121
Current liabilities:  
Accounts payable1,5901,572
Accrued liabilities15,35912,524
Current portion of long-term debt1,4431,591
Total current liabilities18,39215,687
Long-term debt63,17037,354
Long-term deferred tax liabilities2,35411
Long-term tax liabilities4,6805,757
Other noncurrent liabilities2,3262,651
Contingencies and commitments
Stockholders’ equity:  
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—535.4 shares in 2023 and 534.0 shares in 202233,07032,514
Accumulated deficit(26,549)(28,622)
Accumulated other comprehensive loss(289)(231)
Total stockholders’ equity6,2323,661
Total liabilities and stockholders’ equity$ 97,154$ 65,121
AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
 CEO
 WEBSITEamgen.com
 INDUSTRYPharmaceuticals
 EMPLOYEES25200

Amgen Inc Frequently Asked Questions


What is the ticker symbol for Amgen Inc? What does AMGN stand for in stocks?

AMGN is the stock ticker symbol of Amgen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amgen Inc (AMGN)?

As of Fri Apr 19 2024, market cap of Amgen Inc is 144.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers. The fair value of Amgen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amgen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amgen Inc a good stock to buy?

The fair value guage provides a quick view whether AMGN is over valued or under valued. Whether Amgen Inc is cheap or expensive depends on the assumptions which impact Amgen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMGN.

What is Amgen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, AMGN's PE ratio (Price to Earnings) is 21.46 and Price to Sales (PS) ratio is 5.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amgen Inc's stock?

In the past 10 years, Amgen Inc has provided 0.112 (multiply by 100 for percentage) rate of return.